Health Care [ 11/12 ] | Biotechnology [ 66/74 ]
NASDAQ | Common Stock
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases.
The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I).
The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease.
The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015.
Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 5, 25 | -0.78 Increased by 0.00% | -0.70 Decreased by -10.75% |
| Feb 25, 25 | -0.67 Increased by +22.09% | -0.85 Increased by +20.79% |
| Nov 5, 24 | -0.63 Increased by +12.50% | -0.61 Decreased by -3.28% |
| Aug 1, 24 | -0.59 Decreased by -145.38% | -0.69 Increased by +14.49% |
| May 7, 24 | -0.78 Increased by +2.50% | -0.70 Decreased by -11.43% |
| Feb 27, 24 | -0.86 Decreased by -14.67% | -0.80 Decreased by -7.50% |
| Nov 7, 23 | -0.72 Increased by +14.29% | -0.80 Increased by +10.00% |
| Aug 8, 23 | 1.30 Increased by +370.83% | -0.68 Increased by +291.18% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by N/A% | -132.97 M Decreased by -30.62% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Increased by +100.00% | -114.75 M Increased by +3.95% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by -100.00% | -107.19 M Decreased by -7.89% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by -100.00% | -99.03 M Decreased by -154.00% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by -100.00% | -101.80 M Increased by +7.27% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | -305.04 M Decreased by -3.07 K% | -119.47 M Decreased by -21.07% | Increased by +39.17% Increased by +104.08% |
| Sep 30, 23 | 1.27 M Decreased by -64.40% | -99.35 M Increased by +3.82% | Decreased by -7.84 K% Decreased by -170.17% |
| Jun 30, 23 | 294.12 M Increased by +460.45% | 183.38 M Increased by +411.91% | Increased by +62.35% Increased by +155.65% |